Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine driving safety study
NCT02228239Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Standard Deviation of Lateral Position. Started Sep 2014; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02228239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228239.